CFM
MAIA icon

Catalyst Funds Management’s MAIA Biotechnology MAIA Stock Holding History

Catalyst Funds Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,800
Closed -$15.1K – 790
2026
Q1 		$15.1K Buy
+10,800
New +$19.9K ﹤0.01% 579

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Catalyst Funds Management's MAIA Position: Q2 2026 in Review

Catalyst Funds Management sold out of MAIA Biotechnology (MAIA) in Q2 2026, closing a stake of 10,800 shares — an estimated $15.1K sold.

Catalyst Funds Management first reported a position in MAIA in Q1 2026 and held it in 1 quarter. The position peaked at $15.1K in Q1 2026. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • Catalyst Funds Management reported no remaining MAIA Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 10,800 MAIA Biotechnology shares in Q2 2026, an estimated $15.1K.
  • Catalyst Funds Management first reported a position in MAIA Biotechnology in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's MAIA Biotechnology position peaked at $15.1K in Q1 2026.
  • 36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.